Introduction {#S0001}
============

Lung cancer is the most common and deadly cancer, contributing to 11.6% of total cancer and 18.4% of total cancer-related mortality. WHO estimates the incident and mortality rate of lung cancer in Indonesia is 12.4 and 10.9 per 100,000, respectively. In males, lung cancer shows higher incidence and mortality (19.4 and 17.4 per 100,000, respectively) than females (6.0 and 5.1 per 100,000, respectively).[@CIT0001]

Epidermal growth factor receptor (*EGFR*) mutation is an important predictive biomarker in lung cancer targeted therapy. Common mutations such as deletion (del) of exon 19 and L858 substitution mutations in exon 21 predict tumor sensitivity to first-generation tyrosine kinase inhibitors (TKI) such as gefitinib and erlotinib.[@CIT0002],[@CIT0003] There are also rare/uncommon mutations such as G719X and L861Q that confer variable therapeutic responses to TKI treatment.[@CIT0004]--[@CIT0006] On the other hand, there are some oncogenic mutations, such as *EGFR* T790M, insertions of exon 20 of *the EGFR* gene, and *K-RAS*, that contribute to primary and/or acquired resistance to TKI.[@CIT0007],[@CIT0008] Moreover, baseline *K-RAS* mutation either alone or together with *EGFR* mutation may have negative[@CIT0009] or neutral[@CIT0010],[@CIT0011] outcomes to chemotherapy.

Gender, ethnicity, histology and smoking history are known factors affecting prevalent of *EGFR* and *K-RAS* mutations.[@CIT0012],[@CIT0013] *EGFR* mutations generally occur in nonsmoker, female, East Asian, and adenocarcinoma patients. On the other hand, *K-RAS* mutations were observed mainly in western or European patients and may be associated with smoking history.[@CIT0014] Moreover, *K-RAS* mutation is typically showing transversion purine to pyrimidine substitution subtypes a signature of smoking history.[@CIT0015] *EGFR* and *K-RAS* mutations are thought to be mutually exclusive[@CIT0016] although there are reports showing some cases of simultaneous mutations both in European and Asian patients albeit with various rates (0.4--1.1%).[@CIT0017]--[@CIT0021]

We have recently reported the frequency of *EGFR* mutations (44%) in a large retrospective study[@CIT0022] of newly diagnosed lung cancer patients using cytological specimens. Smoking is highly prevalent among male Indonesians[@CIT0023] and has contributed to a major proportion of lung cancer incidence.[@CIT0024] However, the impacts of smoking to the prevalence of *EGFR* and *K-RAS* mutations in Indonesian lung cancer patients have not been analyzed.

Recent meta-analyses evaluating different histopathology, gender and ethnicities have described the likelihood of *ALK-EML4* translocations, and *EGFR* and *KRAS* mutations among lung cancer patients with or without smoking history. Never smoker (NS) patients tend to have higher rates of *EGFR* mutations and *ALK-EML4* translocations than ever smoker (ES) patients. On the other hand, NS patients are less likely to bear KRAS mutations than ES patients. Other factors, such as ethnicities, gender, and histopathology are also associated with key driver mutations in lung cancer.[@CIT0013]

We aimed to evaluate the impact of smoking on the incidence and spectrum of *EGFR* and *K-RAS* gene mutations in lung cancer patients referred to Jakarta tertiary hospital.

Methods {#S0002}
=======

Patients {#S0002-S2001}
--------

A total of 143 newly diagnosed non-consecutive lung cancer patients with known *EGFR* mutation status were enrolled to participate in prospective disease monitoring study. DNA was also genotyped for baseline *K-RAS* mutations. Patients' age ranged from 26 to 84 years, with median of 55 years and average of 53.7 years. Ethical Committee of Faculty of Medicine Universitas Indonesia, Jakarta (396/UN2.F1/ETIK/2016) approved this study. The study was performed in accordance with the 1964 Helsinki declaration and its later Amendments. All patients had signed informed consent.

DNA isolation {#S0002-S2002}
-------------

Cytological specimens were obtained as malignant pleural effusion as well as from fine needle aspirations, bronchoscopies, and transthoracic needle biopsies. Pathologists had marked areas with enriched tumor cells in the cytological specimens. Marked areas were then subjected to DNA isolation using QIAmp DNA Micro (Qiagen NV, Venlo, the Netherlands) according to the kit protocol.

EGFR mutation detection {#S0002-S2003}
-----------------------

The method used for mutation detection is PCR high resolution melting (PCR-HRM), restriction fragment length polymorphism (RFLP), and sequencing as described.[@CIT0022] Briefly, PCR-HRM was used to screen for mutations in exon 18, 19, and 21. Suspected specimens showing mutation specific melting profiles were subjected to genotyping using direct sequencing (exon 18), fragment sizing (exon 19) and RFLP (exon 21 L858R and L861Q). Mutation detection in exon 20 was performed using direct sequencing.

### PCR HRM of EGFR of exons 18, 19, and 21 {#S0002-S2003-S3001}

PCR-HRM was performed in 25 μL reaction volume, containing 200 nM of each forward in reverse primer, 200 μM dNTP, 1 × buffer, 2.5 mM MgCl~2~, 1.25 U of HotStarTaq (Qiagen) polymerase, 1 μL of template, 5 μM Syto-9 (Invitrogen) and PCR grade water. PCR-HRM analysis was performed on Rotor gene 6000^TM^ in the following conditions: 95°C (15 min), followed by 10 cycles of 95°C (10 s), 65°C (10 s) with touchdown for (1 cycle/1°C), 72°C (30 s), 40 cycles of 95°C (10 s), 55°C (10 s), 72°C (30 s), one cycle of 97°C (1 s). The HRM condition was: melt from 80°C to 90°C, rising 0.1°C per second.

### PCR and RFLP of EGFR exon 21 {#S0002-S2003-S3002}

RFLP was performed for exon 21, to detect point mutation in codon 858 and 861. The products of PCR-HRM were digested using MSC I and PVU II enzyme, to detect mutation on codon 858 and 861. To detect the mutation in codon 858, the reaction performed in 25 μL of reaction, consists of: 10 μL of PCR product, 5 U of MSC (NEB), 1 × buffer, and ddH~2~O. Another reaction was performed to detect the mutation in codon 861 using 10 U of PVU II (NEB), 1 × buffer, 10 μL PCR product and then ddH~2~O added until the reaction volume reached 25 μL. RFLP was performed on 37°C for 3--16 h.

### PCR and sequencing of exons 18 and 20 {#S0002-S2003-S3003}

For exon 18, the product of PCR-HRM was purified using Exo Sap IT. Direct sequencing was performed using Applied Biosystems 3,500 Genetic Analyzer (Thermo Fisher Scientific, Waltham, MA, USA).

PCR of exon 20 was performed in 25 μL reaction volume, containing: 1 × buffer, 1.5 mM MgCl~2~, 500 nM of forward primer and 500 nM reverse primer, 200 μM of dNTPs, 1.25 U of HotStar Taq polymerase (Qiagen), 1 μL of DNA template and PCR grade water. The PCR was performed using Veriti Thermal Cycler (Thermo Fisher Scientific) in the following conditions: 95°C (15 min), followed by 40 cycles of 95°C (30 s), 57°C (30 s), 72°C (30 s), one cycle of 72°C (7 min).Table 1DemographyCharacteristicsN (143)Percent**Gender** Male10271% Female4129%**Age** Median55 Average53.7 Range26‒84**Smoking History** Ever smokers (ES)8962% Never smokers (NS)5136% Unknown3**All adenocarcinomaEGFR Genotypes** Wild type (normal)5236% Mutations9164%  Common Mutations (Exon 19 Dels, L858R)6167%  Uncommon mutations (G719X, L861Q, T790M)1719%  Mix mutations1314%***K-RAS* Genotypes** Wild type13393% Mutations107.0%  Transversion660%  G12C4  G12A1  G12R1  Transition440%  G12D3  G12S1**Mix *EGFR* and *K-RAS* concomitant mutations**42.8% K-RAS mutations in 91 EGFR Mutant patients4.4% EGFR mutations in 10 K-RAS mutant patients40%

K-RAS mutation detection {#S0002-S2004}
------------------------

PCR and direct sequencing of *K-RAS* mutations were performed as described.[@CIT0025] Briefly, RAS SplitSCAN (KalgenDNA, Jakarta, Indonesia) HRM primers were used to screen a hotspot mutation of exon 2 of the *K-RAS* gene. Samples were ran using Rotor-Gene 6000TM (Corbett Life Science, Mortlake, Australia) or Rotor-gene Q (Qiagen). Melting curves were generated and scanned for the presence of split peaks predicting the presence of mutations. Samples showing putative mutated split peak patterns were then genotyped using direct DNA sequencing.

### PCR HRM of KRAS exon 2 {#S0002-S2004-S3001}

PCR HRM was performed in 20 μL reaction volume containing 200 nM of each forward in reverse primer, 200 μM dNTP, 1 × buffer, 2.5 mM MgCl~2~, 1 U of HotStarTaq (Qiagen) polymerase, 1 μL of template, 5 μM Syto-9 and PCR grade water. HRM analysis was performed on the Rotor-Gene 6000^TM^ in the following conditions: 95°C (15 min), followed by 50 cycles of 95°C (10 s), 68°C (10 s), 72°C (20 s), one cycle of 95°C (1 s), one cycle of 95°C (1 s), melt from 72°C to 90°C, rising 0.1°C per second.

### PCR and sequencing of KRAS exon 2 {#S0002-S2004-S3002}

Conditions for first PCR reaction were 95°C (4 mins), followed by 25 cycles of 95°C (30 s), 50°C (30 s), 72°C (30 s), and 1 cycle of 72°C (7 min). PCR reaction performed in 25 μL reaction volume, containing: 1 × buffer, 1.5 mM MgCl~2~, 500 nM of forward primer and 500 nM reverse primer, 200 μM of dNTPs, 1.25 U of Faststart Taq (Roche) polymerase, 1 μL of DNA template and PCR grade water. First PCR product diluted to 1:10, and 1 μL of the diluted product used as template for nested PCR. Nested PCR was performed in the following conditions: 95°C (4 min), followed by 35 cycles of 95°C (30 s), 55°C (30 s), 72°C (30 s), and 1 cycle of 72°C (7 min). PCR reaction performed in 25 μL reaction volume, containing 1 × buffer, 1.5 mM MgCl~2~, 300 nM of forward primer and 300 nM reverse primer, 200 μM of dNTPs, 1.25 U of Faststart Taq (Roche) polymerase, DNA template and PCR grade water.

Statistical analysis {#S0002-S2005}
--------------------

Categorical variables were summarized by frequency and percentage. Pearson's chi-squared test (or Fisher's exact test if cell frequencies less than 5 were expected) was used to test for associations between patient characteristics and mutation type and smoking status. A two-sided *p*-value of less than 0.05 was taken as statistically significant.

Results {#S0003}
=======

Prevalence of *EGFR* and *K-RAS* mutations {#S0003-S2001}
------------------------------------------

A total of 143 newly diagnosed non-consecutive patients with adenocarcinoma histology had been genotyped for *EGFR* and *K-RAS* mutations. Most patients were males (71%), and the majority (64%) was smokers ([Table 1](#T0001){ref-type="table"}). Common *EGFR* mutations (exon 19 indels and L858R) were the major (67%) subtypes, followed by uncommon mutations (19%, G719X, T790M, and L861Q), and mix or compound (14%) mutation subtypes. *K-RAS* mutation frequency was 7%, and *K-RAS* transversion mutation (60%) was slightly more common than transition mutation (40%, *p*\> 0.05). Moreover, *K-RAS* mutation rate was slightly higher in females, 3 of 39 (7.6%, *p*= 1.0), than males, 6 of 101 (5.9%). The rate of concomitant or simultaneous *EGFR* and *K-RAS* mutations in the same individuals was 2.8% (or 4 out of 143 patients).

Impact of smoking history on *EGFR* mutation rate {#S0003-S2002}
-------------------------------------------------

When stratified according to smoking history, *EGFR* mutation was higher in NS (75%, *p*= 0.0465) than ES (57%) ([Table 2](#T0002){ref-type="table"}). Furthermore, young NS had also more frequent *EGFR* mutation rate than ES patients (81% vs 53%, *p*= 0.0343). The trend toward higher *EGFR* mutation rate was also observed in NS males than ES males (82% vs 57%, *p*= 0.06), but did not reach statistical significance (see [Figure 1](#F0001){ref-type="fig"}). Similar EGFR mutation frequency was also observed in females (71% in NS females vs 60% in ES females, *p*= 0.63 see [Figure 1](#F0001){ref-type="fig"}). Mix or multiple *EGFR* mutations containing both common and uncommon *EGFR* mutants in the same individuals seemed to be more prevalent in smoker (20%) vs nonsmoker (5%, *p*= 0.0632) patients ([Table 2](#T0002){ref-type="table"}).Table 2Impact of smoking history to prevalence and spectrum of *EGFR* mutationCharacteristics*EGFR* genotypes\**p*-value*EGFR* mutation types\**p*-valueWild typesMutantsCommonUncommonMixSmoking historyEver smokers893843%5157%0.04653365%816%1020%0.0632Never smokers511325%3875%2771%924%25%Unknown3Age 55 years old and youngerEver smokers512447%2753%0.03431556%726%519%0.139Never smokers21419%1781%1165%635%00%Age older than 55 years oldEver smokers381437%2463%0.61271875%14%521%0.421Never smokers30930%2170%1676%314%210%MaleEver smokers843643%4857%0.063063%817%1021%0.429Never smokers17318%1482%1071%321%17%FemaleEver smokers5240%360%0.633100%00%00%1Never smokers341029%2471%1771%625%14%[^1] Figure 1*EGFR* and *K-RAS* mutation rates in males and females with or without smoking history.**Abbreviations:** ES, ever smokers; NS, nonsmokers.

Impact of smoking history on *K-RAS* mutation rate {#S0003-S2003}
--------------------------------------------------

When stratified according to smoking history, *K-RAS* mutation was slightly higher in ES (7%, *p*= 1.0) than NS (6%) ([Table 2](#T0002){ref-type="table"}). ES male patients had a tendency of a higher rate of *K-RAS* mutation (7.5%) than NS male patients (0%, *p*= 0.56) ([Table 3](#T0003){ref-type="table"}, [Figure 1](#F0001){ref-type="fig"}). A signature of smoke-associated mutation, *K-RAS* mutation transversion type (mainly *K-RAS* G12C) was also consistently more frequent in ES than NS patients. On the other hand, *K-RAS* mutation rate and patterns (transversion or transition) among females were independent of smoking history ([Table 3](#T0003){ref-type="table"}).Table 3Impact of smoking history to prevalence and spectrum of *K-RAS* mutation*K-RAS* WT*K-RAS* mutation\**p*-valueTransversionTransitionsTotalnRatenRatenRatenRate14013194%96%Smoking historyEver smokers898393%67%1.00467%233%Never smokers514894%36%133%267%Unknown355 years and underEver smokers514792%48%1.00250%250%Never smokers211990%210%00%2100%Older than 55 yearsEver smokers383695%25%1.002100%00%Never smokers302997%13%1100%00%Male1019594%66%Ever smokers847893%67%0.56467%233%No smokers1717100%00%0-0-Female393693%37%Ever smokers55100%00%1.000-0-Never smokers343191%39%133%267%

Double mutation of *EGFR* and *K-RAS* genes {#S0003-S2004}
-------------------------------------------

Of the 143 patients, 4 (4.4%) had simultaneous *EGFR* and *K-RAS* gene mutations ([Table 4](#T0004){ref-type="table"}, [Figure 1](#F0001){ref-type="fig"}). *K-RAS* mutation transversion types (G12C) were found with *EGFR* L858R mutation. Within our cohort, *EGFR* exon 19 deletion was never found together with *K-RAS* mutations. Although not statistically significant, frequency of double *EGFR* and *K-RAS* mutations was higher in young (3 of 52 or 6%) than old patients (1 of 91 or 1%, *p*\> 0.05). Patients having uncommon or mix *EGFR* mutations also tend to harbor additional *K-RAS* gene mutation (3 of 30 or 10%) than those having *EGFR* common mutations only (1 of 61 or 1.6%, *p*\> 0.05). Lastly, NS patients tend to have a higher frequency of concomitant *EGFR* and *K-RAS* mutations (2 of 51, 3.9%) than ES patients (1 of 89 or 1.1%, *p*\> 0.05).Table 4Clinical characteristic of *EGFR* and *K-RAS* double mutationsGenderAge (years)Smoking history*EGFR* in cytology*K-RAS* mutation*K-RAS* mutation typesFemale84Never smokerL858RG12CTransversionMale46UnknownT790M, G719S, L858RG12CTransversionMale42Ever smokerG719SG12STransitionFemale41Never smokerL861Q, T790MG12DTransition

Discussion {#S0004}
==========

A meta-analysis by Dearden et al showed that *EGFR* mutations occurred more frequently in Asian than Western patients (47.9% versus 19.2%), while *K-RAS* mutations are more frequent in Western than Asian patients (KRAS, 26.1% versus 11.2%).[@CIT0026] The overall rates of *EGFR* and *K-RAS* mutations in this study confirmed the Asian profile. Patients with smoking history had 56% *EGFR* mutation rate, similar to other Asian studies,[@CIT0027],[@CIT0028] confirming the importance of *EGFR* testing regardless of smoking history. In the current study, we also found a consistent trend of higher *EGFR* mutation in NS patients compared to ES patients (see [Figure 1](#F0001){ref-type="fig"}). However, the difference in *EGFR* mutation rates in NS vs ES female patients was not statistically significant. It is probably related to low numbers of female ES patients enrolled in this study (only 5 ES females out of a total of 39 patients). Nevertheless, a recent study enrolling a large number of ES female patients from seven Asian regions indeed demonstrated more frequent *EGFR*mutations in NS females (62%, N=358) than ES females (51%).[@CIT0029] Another study by Hsiao et al also showed higher rates of EGFR mutations in NS females compared to ES females (60% vs 29%, N=426).[@CIT0030]

Within our cohort, there was a trend toward more frequent uncommon *EGFR* mutations among ES patients, although statistically not significant, which is consistent with other Asian studies.[@CIT0004],[@CIT0031] On the other hand, a significant association of *EGFR* uncommon mutations with smoking has been described amongst European lung cancer patients.[@CIT0032]

Overall *K-RAS* mutation rate in this study (7%) was also similar to other Asian studies (around 8--10%), which is generally lower than Western patients (25--30%).[@CIT0026],[@CIT0033] Our results also showed a consistent tendency of a high frequency of *K-RAS* mutations among smokers. Smoking history association with *K-RAS* mutations has been shown in many studies,[@CIT0033] with G12C or transversion mutation type being most common in smokers. We also observed that *K-RAS* mutation G12C (transversion) types were frequent among male ES. However, our study and others have also shown that the association between smoking history and *K-RAS* mutation may not necessarily be strict.[@CIT0034] For instance, we did find some *K-RAS* mutations among NS patients having concurrent *EGFR* and *K-RAS* mutations ([Figure 1](#F0001){ref-type="fig"}).

The significance of *K-RAS* mutations in women with smoking history has been described. The study suggests that women are more susceptible to smoking-related lung cancer because they have higher rates of *K-RAS* G12C mutations occurring in a younger age of diagnosis and with fewer pack-years of smoking than men with the same mutations.[@CIT0035] However, in our cohort, we did not find any *K-RAS* mutations in ES females. Instead, *K-RAS* G12D types mutations were found in NS females. Therefore, future studies may characterize driver mutations in Indonesian ES females.

Recent review[@CIT0036] shows a higher tendency of *K-RAS* mutation frequencies in smokers (25%) and male patients (22%) than nonsmokers (6%) and female patients (20%). In our study, the mutation frequency among ES patients and male gender in this study was modest (7%). Asian studies in Japan, Korea, and China show that the rates of *K-RAS* mutations among male patients are 14%, 23%, and 33%, respectively.[@CIT0017],[@CIT0037],[@CIT0038] This relatively low frequency of KRAS mutations in male and ES patients was unexpected, given the high prevalence of cigarettes consumptions among Indonesian men.[@CIT0039] Between 85% and 90% of all cigarettes smoked in Indonesia are kreteks, a type of clove cigarette with high tar content.[@CIT0023],[@CIT0040]

In addition, we speculate that the extensive use of woods as solid fuels for cooking that are prevalent among up to 50% of the Indonesian population[@CIT0041] may affect the rate of *K-RAS* mutation as described in a Mexican study.[@CIT0042] Lung cancer patients exposed to wood smokes have a low frequency of *K-RAS* mutations regardless of cigarettes smoking history. Therefore, future studies may explore lifestyle and environmental related *K-RAS* gene and possibly other oncogenic driver mutations in Indonesia.

*EGFR* and *K-RAS* mutations are thought to be mutually exclusive.[@CIT0033] However, in our cohort, *EGFR* and *K-RAS* co-mutation frequency was 2.8% overall or 4.6% (of *EGFR* mutation positive cases). In Asia the rate is 0.25% (6 *K-RAS* mutation cases of 2,387 *EGFR* mutation positive) or 1.5% (6 *EGFR* mutations of 398 *K-RAS* mutation positive),[@CIT0043] 1.5% (29 of 1,854 *EGFR* mutation cases) or 6.7% (29 of 429 cases).[@CIT0019]

In Taipei, *K-RAS* mutation rate was 8.3%, while concomitant *K-RAS* and *EGFR* mutation rate was 1.4% (1 out of 69 *EGFR* mutation positive).[@CIT0018] In a Chinese study, 1 *K-RAS* (0.3%) mutation has been found in 320 *EGFR* mutation positive patients.[@CIT0044] In Western patients overlapping *EGFR* and *K-RAS* mutations represented 6.8% (3 of 44) and 3.2% (3 of 92) of the population with single *EGFR* or *K-RAS* mutations, respectively.[@CIT0045] Among Asians, our rate of concurrent *K-RAS* and *EGFR* gene mutations seemed to be the highest. Moreover, other studies[@CIT0019],[@CIT0046] show that Del19 EGFR mutations occur together with KRAS mutations, which are not observed in our cohort. In a recent large study, concurrent mutation is associated with non-smoking patients and may affect progression-free survival, but not overall survival.[@CIT0047] These accumulated data may reconsider a given dogma of *EGFR* and *K-RAS* mutually exclusive mutations in lung cancer.[@CIT0047] Furthermore, conflicting prognostic and/or predictive utility of baseline *K-RAS* mutations to chemotherapy may question the clinical utility of *K-RAS* genotyping in lung cancer.[@CIT0048] Interestingly, a recent commentary on promising results of selumetinib, a potent inhibitor of mitogen-activated protein kinase 1 (*MEK1*) and *MEK2* has pointed out an association of *K-RAS* G12C mutations and good response rate.[@CIT0049] Therefore, future studies may clarify the roles of *K-RAS* mutation in the routine management of lung cancer patients.
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[^1]: **Notes:**\* *p*-value \<0.05 were statistically significant.
